register

News & Trends - Pharmaceuticals

Medicines Australia welcomes consultation on a national approach to clinical trials

Health Industry Hub | July 20, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Medicines Australia welcomes the clinical trial ‘one-stop-shop’ consultation, recently announced by the Australian Commission on Safety and Quality in Health Care.

Clinical trials in Australia are a significant enabler for faster access for patients and make an important contribution to the economy but we require a consistent, national approach to remain competitive. This newly launched consultation presents an opportunity to achieve a national, interconnected, rapid and streamlined pathway for attracting clinical trials to our shores.

The COVID-19 pandemic drew the world’s attention to the benefits of clinical trials. These have been well documented, such as job creation, better health outcomes for patients and an increased body of scientific knowledge and medical innovation. In 2019, the biopharmaceutical industry is estimated to have invested over $1 billion in Australia for clinical trials.

Australia has been an attractive environment for clinical trials and R&D, but many large companies stumble at the first hurdle due to the inconsistent processes between the different states and territories.

Last night, Medicines Australia CEO, Elizabeth de Somer, spoke on ABC Nightlife and says that clinical trials remain a crucial path to bring innovative drugs, vaccines and therapies to patients in Australia in a safe and regulated manner.

“Clinical trials are critical for a lot of Australian patients, important for our economy and increase our R&D capabilities. We must make our country a more attractive option for international investment,” she said.

Medicines Australia has been working with the Government to harmonise these arrangements, which were also supported by the Minister for Health, the Hon Greg Hunt MP, during his CEDA address in June last year. Since then, considerable progress has been made on this commitment by The Research & Development Task Force (R&DTF), a multi-sector collaboration between Medicines Australia, AusBioTech and the Medical Technology Association of Australia (MTAA). The one-stop-shop consultation is the next step in this vital work.

Elizabeth was joined on the ABC Nightlife program by clinical trial participant Karen Van Gorp and Professor Meg Jardine, Director of Sydney University Clinical Trials Centre.

A recording of the interview is available on the ABC website.


Medical

Medical Pharma Biotech MedTech - Achieving gender equity for female researchers - Professor Julie Campbell, GSK award winner

Achieving gender equity for female researchers – Professor Julie Campbell, GSK award winner

Health Industry Hub | August 6, 2021 |

Medical News: GSK Australia Award for Research Excellence (ARE) is one of the most prestigious and long-standing awards available to […]

More


News & Trends - Medical Technology

MedTech News - Baxter Healthcare launches on-site pop-up COVID vaccination clinic

Baxter launches on-site pop-up COVID vaccination clinic

Health Industry Hub | August 6, 2021 |

MedTech News: Baxter Healthcare has launched an on-site pop-up vaccination clinic at its Western Sydney site this week to support […]

More


News & Trends - Pharmaceuticals

Pharma News - Cancer treatments minimally impacted during COVID-19 lockdowns in Australia, new study

Cancer treatments minimally impacted during COVID-19 lockdowns in Australia, new study

Health Industry Hub | August 6, 2021 |

Pharma News: Australian cancer patients kept up their pharmaceutical treatments during last year’s COVID-19 lockdowns, a big data study from […]

More


News & Trends - Pharmaceuticals

Pharma News - Could PARP inhibitors benefit more ovarian cancer patients?

Could PARP inhibitors benefit more ovarian cancer patients?

Health Industry Hub | August 6, 2021 |

Pharma News: Researchers have made a discovery that could help more Australian women with ovarian cancer gain access to game-changing […]

More